doc. MUDr. Norbert Pauk, Ph.D. ****************************************************************************************** * ******************************************************************************************
Department of Pneumology 3FM CU and UHB https://www.lf3.cuni.cz/3LF-1324.html [ URL "https://www.lf3.cuni.cz/3LF-1324.html"] www.bulovka.cz/pneumologie [ URL "http://www.bulovka.cz/pneumologie"] Topic title Pneumology *========================================================================================= * Description of scientific activity *========================================================================================= Our mainstay programs include the care of patients with lung cancer. We are the largest pn center, diseases associated with airway obstruction (we are the National Center for Severe Dr. Pauk), interstitial lung processes (we are the Center for Interstitial Lung Diseases i and sleep-disordered breathing, and we are involved in indications for home non-invasive v physicians are authors of national guidelines). We are joining a national initiative for b cancer screening and COPD (chronic obstructive pulmonary disease). The Clinic closely coop the Surgical Clinic of the 1st Faculty of Medicine, IPVZ, the Institute of Radiation Oncol Faculty of Medicine and other departments of the Faculty Hospital Bulovka and also the Fac Královské Vinohrady. The clinic cooperates in several lung disease registries (Lung Cancer project, COPD and Cesar project - for difficult-to-treat asthma). We present the results o a lot of national and international conferences and publications. Thus, our clinical resea pneumooncology, severe asthma, interstitial lung diseases and COPD. I review articles for *========================================================================================= * Selected publications *========================================================================================= Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis (INMARK study): a randomised, placebo-controlled study. Stowasser S2, Nishioka Y3, White E Noth I6, Selman M7, Rohr KB2, Michael A8, Ittrich C9, Diefenbach C9, Jenkins RG10; Lancet Sep;7(9):771-779. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. Horn Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio M Lam S, Shames DS, Liu J, Ding B, Lopez-Chavez A, Kabbinavar F, Lin W, Sandler A, Liu SV; I Group. 2018 Dec 6;379(23):2220-2229NEJM Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLAN label, single-arm, phase 2 study. MC1, Cho BC2, Kim JH3, Mazi?res J4, Vansteenkiste J5, Le Jaime J7, Gray JE8, Powderly J9, Chouaid C10, Bidoli P11, Wheatley-Price P12, Park K13, So Y15, Wadsworth C16, Dennis PA15, Rizvi NA17; Lancet Oncol. 2018 Apr;19(4):521-536. *========================================================================================= * Selected or ongoing grants/clinical studies *========================================================================================= Clinical trials: lung cancer, interstitial lung diseases, COPD, asthma bronchiale *========================================================================================= * PhD Students *========================================================================================= Number of PhD students currently studying : 1 Number of defended students with year of defence: 2 (2013, 2014)